You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • AB0034 Pharmacokinetics and Safety of BCD-057, Adalimumab Biosimilar Candidate, Compared To Humira in Healthy Volunteers (Results of Phase I Clinical Study)

Citation Tools

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Cytokines and inflammatory mediators
AB0034 Pharmacokinetics and Safety of BCD-057, Adalimumab Biosimilar Candidate, Compared To Humira in Healthy Volunteers (Results of Phase I Clinical Study)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Eremeeva A, Fogt S, Chernyaeva E, et al
AB0034 Pharmacokinetics and Safety of BCD-057, Adalimumab Biosimilar Candidate, Compared To Humira in Healthy Volunteers (Results of Phase I Clinical Study)
Annals of the Rheumatic Diseases 2016;75:908.